Partners Capital Investment Group’s BridgeBio Pharma BBIO Stock Holding History

Partners Capital Investment Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,371	Closed	-$12K	–	134
2022 Q2	$12K	Hold	1,371	–	–	﹤0.01%	124
2022 Q1	$14K	Sell	1,371 -483,002	-100%	-$4.96M	﹤0.01%	113
2021 Q4	$8.08M	Buy	484,373 +16,245	+3%	+$687K	0.37%	61
2021 Q3	$21.9M	Buy	468,128 +30,674	+7%	+$1.64M	1%	42
2021 Q2	$26.7M	Buy	+437,454	New	+$25M	1.19%	33

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Partners Capital Investment Group's BBIO Position: Q3 2022 in Review

Partners Capital Investment Group sold out of BridgeBio Pharma (BBIO) in Q3 2022, closing a stake of 1,371 shares — an estimated $12K sold.

Partners Capital Investment Group first reported a position in BBIO in Q2 2021 and held it in 5 quarters. The position peaked at $26.7M in Q2 2021. 181 funds tracked by Wall St. Rank hold BBIO as of Q3 2022.

Partners Capital Investment Group reported no remaining BridgeBio Pharma position as of Q3 2022 after selling out during the quarter.
Partners Capital Investment Group sold 1,371 BridgeBio Pharma shares in Q3 2022, an estimated $12K.
Partners Capital Investment Group first reported a position in BridgeBio Pharma in Q2 2021 and held it in 5 quarters.
Partners Capital Investment Group's BridgeBio Pharma position peaked at $26.7M in Q2 2021.
181 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2022.

Based on Partners Capital Investment Group's 13F filing for Q3 2022, filed 14 Nov 2022.